The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis

scientific article published on 13 December 2018

The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2147/OTT.S187239
P932PMC publication ID6300376
P698PubMed publication ID30588018

P50authorHao ZengQ88623996
P2093author name stringPeng Zhao
Jiandong Liu
Pengfei Shen
Guangxi Sun
Xingming Zhang
Jinge Zhao
Junru Chen
Jindong Dai
P2860cites workAndrogen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.Q45930559
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for hiQ46259659
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 studyQ46616101
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyQ46817220
Cancer statistics, 2018.Q47191906
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.Q48535376
Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy.Q51345317
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.Q53041535
Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?Q54566799
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.Q55067996
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independenceQ73146858
Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy aloneQ79823525
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomyQ80744531
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921Q88291250
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataQ26771537
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerQ29616218
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialQ29620155
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916Q33432475
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsQ34013808
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerQ34296696
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerQ34487137
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerQ35967139
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.Q36480632
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialQ36707077
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancerQ37439463
Treatment strategies for high-risk locally advanced prostate cancerQ37671592
What is the pathophysiology of a hormone-resistant prostate tumour?Q37937865
High-risk prostate cancer: from definition to contemporary managementQ37990230
Adaptation and clonal selection models of castration-resistant prostate cancer: current perspectiveQ38060845
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trialQ38392753
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.Q38706310
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trialQ40885260
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.Q42864027
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.Q44114886
Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancerQ44809404
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectchemotherapyQ974135
P304page(s)9061-9070
P577publication date2018-12-13
P1433published inOncoTargets and TherapyQ7092081
P1476titleThe effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis
P478volume11

Search more.